MeiraGTx Holdings plc

What they do

MeiraGTx is a vertically integrated clinical-stage genetic medicines company with a pipeline including AAV2-hAQP1 for radiation-induced xerostomia, bota-vec for X-linked retinitis pigmentosa (XLRP), and a Parkinson's disease program. It operates GMP viral vector manufacturing facilities in London, UK (licensed by MHRA) and Shannon, Ireland, plus a GMP plasmid/DNA production facility, and has developed a riboswitch gene regulation platform for oral small-molecule controlled in vivo expression of biologic therapeutics.

Revenue drivers

• Strategic collaborations and licensing — Revenue comes primarily from upfront and milestone payments, research funding, and royalties from collaborations, including the 2019 Janssen agreement, the 2023 bota-vec sale to Janssen, and the November 2025 Lilly collaboration for ophthalmology genetic medicines.
• Asset sales — In May 2026, MeiraGTx completed the acquisition of full rights to bota-vec from J&J for $25 million, with J&J eligible for a regulatory/commercial milestone and mid-teens royalties starting mid-2029, indicating a shift toward product ownership.
• Contract manufacturing and services — The company's manufacturing facilities in London and Shannon support its own programs and third-party supply obligations, generating service fees; as of June 30, 2026, $30.0 million billed and unbilled receivables from Lilly and Reogen were reported.

Recent performance

For Q2 2026, MeiraGTx reported revenue of $321.4 million, a sharp increase from $75.4 million in Q4 2025 and $293,000 in Q1 2026. Annual revenue rose from $33.3 million in 2024 to $81.4 million in 2025, while net loss improved from -$147.8 million to -$114.2 million year-over-year. Operating cash flow was -$46.4 million in 2025, improving from -$104.5 million in 2024. As of June 30, 2026, cash and equivalents were $143.2 million, with total assets of $396.4 million and shareholder equity of $215.8 million.

Strategy

Management is focused on transitioning to a commercial company, with plans to submit global regulatory filings for bota-vec in 2026 and a potential BLA for AAV2-hAQP1 in mid-2027. They are building internal market access and commercial teams, including senior hires from J&J. The company is also advancing its riboswitch platform, with Ribo-Leptin moving to first-in-human studies and a neuropathic pain program in development. To fund these efforts, they completed a $25 million bota-vec acquisition with a concurrent $100 million equity financing and secured up to $400 million in strategic investment from Oberland Capital, including $375 million in non-dilutive capital.

Risks

• Clinical stage and no product revenues — The company has never generated product revenue and expects continued losses; as of December 31, 2025, accumulated deficit was approximately $816.2 million.
• Regulatory approval uncertainty — Bota-vec and AAV2-hAQP1 are not yet approved; any delays or failures in regulatory submissions could materially impact the business.
• Dependence on collaborations — A significant portion of revenue comes from collaboration partners (Janssen, Lilly); termination or changes in these agreements could hurt financials.
• Manufacturing and commercialization scale-up — The company has not demonstrated ability to complete large-scale pivotal trials, obtain marketing approval, or conduct commercial manufacturing and sales.

Outlook

Management expects to submit global regulatory filings for bota-vec in 2026 and a BLA for AAV2-hAQP1 in mid-2027, with potential first commercial launch in 2027. They are building commercial infrastructure and market access teams, and advancing the riboswitch platform toward clinical studies. The company anticipates continued losses as it invests in development and commercialization.